Presentations & Faculty, July 7 - 8 2023
07:50am
Opening Introduction to the meeting – Ryan Fitzpatrick, CEO, MD Education
Session I
Moderator – Farhad Ravandi and Eytan Stein
The genetic landscape and molecular diagnostics in AML
Joe Khoury, University of Nebraska Medical Center
Optimizing frontline therapy for FLT3 mutated AML patients eligible for Intensive Chemotherapy
Harry Erba, Duke Blood Cancer Center, Durham
Genomic strategies to guide the choice of intensive treatment strategies in non-FLT3m AML
Amir Fathi, Massachusetts General Hospital, Boston
Diagnostic and Molecular Work-up of Newly Diagnosed AML- The Pathologists’ Perspective
Sanam Loghavi, MD Anderson Cancer Center Houston, Texas
9:20am
Panel Discussion
Session II
Moderator – Marina Konopleva and Amir Fathi
Updates on the management and mechanisns of resistance in R/R FT3 mutated AML
Alexander E. Perl, Hospital of University of Pennsylvania, Philadelphia PA
How do I assess for MRD in clinical practice and how do I use MRD to guide post remission therapy
Farhad Ravandi, MD Anderson Cancer Center Houston, Texas
How do I use IDH inhibitors in the frontline and R/R Setting: Single agent versus combinations
Courtney DiNardo, MD Anderson Cancer Center Houston, Texas
Current status and future directions with menin inhibitors in AML
Eytan Stein, Memorial Sloan Kettering Cancer Center, New York
11:20pm
Panel Discussion
Session III
Moderator – Tapan Kadia and Hetty Carraway
The case for upfront triplets
Naval Daver, MD Anderson Cancer Center, Houston, Texas
The case for sequential triplets
Jessica Altman, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
12:50pm
Panel Discussion
Developing immune and cellular therapies in AML
Yasmin Abaza, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
How do I Manage AML Patients Receiving HMA/venetoclax based therapies; A focus on practical approaches
Brian Jonas, UC Davis Health, Sacramento, CA
13:40pm
Panel Discussion
Session IV
Moderator – Alexander Perl and Courtney DiNardo
Mechanisms of resistance and novel combinations with venetoclax based therapies in AML
Marina Konopleva, MD Anderson Cancer Center Houston, Texas
Optimizing maintenance therapy in AML post-consolidation and post-transplant
Tapan Kadia, MD Anderson Cancer Center, Houston, Texas
15:40pm
Panel Discussion
16:00pm
Astellas Sponsored Expert Discussion
Session V
Moderator – Anjali Advani and Ryan Cassaday
Incorperating targeted therapies: Menin, FLT3, IDH and others in pediatric populations
Branko Cuglievan, MD Anderson Cancer Center, Houston, Texas
The genetic landscape and molecular diagnostics in ALL
Charles Mullighan, St. Jude Children’s Research Hospital, Memphis, Tennessee
Walking away from chemotherapy
Elias Jabbour, MD Anderson Cancer Center, Houston, Texas
When to transplant in ALL
Mark Litzow, Mayo Clinic Comprehensive Cancer Center
10:20am
Panel Discussion
Session VI
Moderator – Wendy Stock and Nitin Jain
Inotuzumab
Ryan Cassaday, Fred Hutchinson Cancer Center, Seattle, Washington
Blinatumomab
Anjali Advani, Cleveland Clinic, Ohio
11:30am
Discussion
How to approach Ph-like ALL
Marina Konopleva, MD Anderson Cancer Center, Houston, Texas
How to tailor therapy according to MRD: when to escalate and when to de-escalate
Aaron Logan, University of California, San Francisco
12:20pm
Panel Discussion
Session VII
Moderator – Aaron Logan and Shira Dinner
Immunotherapy in ALL
Elias Jabbour, MD Anderson Cancer Center, Houston, Texas
CAR T-cells in ALL
Bijal Shah, Moffitt Cancer Center, Tampa, Florida
13:50pm
Discussion
BCL2 inhibitors in ALL
Marlise Luskin, Dana-Farber Cancer Institute, Boston, Massachusetts
How to optimize pediatric regimens and the use of asparaginase
Wendy Stock, The University of Chicago
14:40pm
Panel Discussion
Session VIII
Moderator – Bijal Shah and Marina Konopleva
Novel agents and pathways in T-ALL and ETP-ALL
Nitin Jain, MD Anderson Cancer Center, Houston, Texas
Novel CAR T approaches
Regina Myers, Childrens Hospital of Philadelphia
Older adults with ALL
Shira N Dinner, Northwestern Medicine, Feinberg School of Medicine, Chicago, IL
Future of ALL therapies
Hagop Kantarjian, MD Anderson Cancer Center, Houston, Texas
